Paula
Rodríguez Otero
Consultora Médica
Harvard Medical School
Boston, Estados UnidosPublications en collaboration avec des chercheurs de Harvard Medical School (9)
2023
-
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Leukemia Research, Vol. 129
-
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Nature Medicine, Vol. 29, Núm. 3, pp. 632-645
2022
-
Melphalan flufenamide for relapsed/refractory multiple myeloma
Drugs of today (Barcelona, Spain : 1998), Vol. 58, Núm. 8, pp. 407-423
-
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study
British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
European Journal of Haematology, Vol. 108, Núm. 1, pp. 73-83
2021
-
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767
2020
-
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1850-1859
-
Melflufen for relapsed and refractory multiple myeloma
Expert Opinion on Investigational Drugs, Vol. 29, Núm. 10, pp. 1069-1078